Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME LANDMAN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1346204690
CMS profile
105508
Location
AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$290.90

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $290.90 12

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $123.34 6
Teva Pharmaceuticals USA, Inc. $98.51 2
PFIZER INC. $69.05 4

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME LANDMAN

NPI 1346204690 · CMS profile ID 105508

Allopathic & Osteopathic Physicians / Allergy & Immunology

AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1346204690?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $290.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $17.5011/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673645453 CMS
GlaxoSmithKline, LLC. $17.9811/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671452985 CMS
PFIZER INC. $17.0010/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673308605 CMS
PFIZER INC. $11.3508/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673271345 CMS
PFIZER INC. $23.2007/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673263469 CMS
GlaxoSmithKline, LLC. $16.9406/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671371539 CMS
GlaxoSmithKline, LLC. $24.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670576149 CMS
Teva Pharmaceuticals USA, Inc. $70.4905/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697805199 CMS
Teva Pharmaceuticals USA, Inc. $28.0205/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697707737 CMS
GlaxoSmithKline, LLC. $20.5204/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671487659 CMS
GlaxoSmithKline, LLC. $20.5202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670670245 CMS
GlaxoSmithKline, LLC. $22.5201/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670938407 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $290.90 12
PY2020 $140.24 7
PY2021 $151.53 7
PY2022 $161.81 7
PY2023 $108.04 5
PY2025 $185.24 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $751,515.35 131
PY2024 Principal investigator $525,143.48 126
PY2023 Principal investigator $497,961.58 102
PY2022 Principal investigator $447,451.34 86
PY2021 Principal investigator $586,667.15 102
PY2020 Recipient $11,702.26 1
PY2020 Principal investigator $473,131.41 28
PY2019 Recipient $1,525.00 1
PY2019 Principal investigator $615,806.88 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $780.34 12/31/2021 Non-covered Recipient Entity
FLORIDA CTR FOR ALLERGY AND ASTHMA
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 826458613
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 12/22/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256209
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,558.81 12/14/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255989
Principal investigator 1 GlaxoSmithKline, LLC. $5,493.00 12/08/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 860868827
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 11/23/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255755
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 11/23/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255757
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,745.96 11/23/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255773
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 11/23/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256205
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,245.00 11/16/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256055
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $399.00 11/16/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256091
Principal investigator 1 GlaxoSmithKline, LLC. $19,814.40 11/12/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 809508237
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,347.00 11/10/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256045
Principal investigator 1 GlaxoSmithKline, LLC. $8,870.00 11/09/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 860871147
Principal investigator 1 GlaxoSmithKline, LLC. $222.88 11/06/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 860872305
Principal investigator 1 GlaxoSmithKline, LLC. $42,773.28 10/28/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 860867883
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,410.63 10/26/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255771
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 10/26/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255871
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $449.00 10/26/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256067
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 10/19/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255751
Principal investigator 1 GlaxoSmithKline, LLC. $167.16 10/13/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 809547221
Principal investigator 1 GlaxoSmithKline, LLC. $8,400.00 10/13/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 860871145
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,116.29 10/07/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF REMIBRUTINIB (LOU064) TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY FOR 52 WEEKS IN ADULT CHRONIC SPONTANEOUS URTICARIA (CSU) PATIENTS INADEQUATELY CONTROLLED BY H1-ANTIHISTAMINES No dispute reported 06/30/2026 800629753
Principal investigator 1 GlaxoSmithKline, LLC. $806.40 10/06/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 809547215
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.65 10/04/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 860871381
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $399.00 09/29/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256095
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $26,971.11 09/28/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255715
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.65 09/27/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 860871383
Principal investigator 1 GlaxoSmithKline, LLC. $5,396.40 09/24/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 860868093
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,031.08 09/21/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255705
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,694.00 09/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256057
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.65 09/16/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809541393
Principal investigator 1 GlaxoSmithKline, LLC. $2,347.65 09/16/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 860867881
Principal investigator 1 GlaxoSmithKline, LLC. $4,420.80 09/08/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 860871607
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,289.14 08/31/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255701
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,320.30 08/24/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255719
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,104.36 08/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255721
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 08/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255865
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 08/10/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255859
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,317.70 08/03/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255695
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,082.00 07/29/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256075
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $146.67 07/29/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256111
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 07/22/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809546367
Principal investigator 1 GlaxoSmithKline, LLC. $2,683.80 07/22/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809546373
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $19,243.36 07/20/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255711
Principal investigator 1 GlaxoSmithKline, LLC. $2,683.80 07/12/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809517167
Principal investigator 1 GlaxoSmithKline, LLC. $167.16 07/08/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809546271
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,977.65 07/07/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255699
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 07/07/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255861
Principal investigator 1 GlaxoSmithKline, LLC. $2,386.80 06/28/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809495337
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,694.00 06/28/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256071
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,640.06 06/28/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256107
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 06/24/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809495339
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 06/24/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809505865
Principal investigator 1 GlaxoSmithKline, LLC. $8,567.16 06/23/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 809495405
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,531.00 06/16/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256051
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 06/15/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255607
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,655.47 06/15/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255645
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,400.00 06/10/2021 Non-covered Recipient Entity
FLORIDA CTR FOR ALLERGY AND ASTHMA
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 826476387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,642.63 06/02/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255635
Principal investigator 1 GlaxoSmithKline, LLC. $2,683.80 05/27/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809525807
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,837.00 05/20/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256061
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,479.32 05/18/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255619
Principal investigator 1 GlaxoSmithKline, LLC. $5,070.60 05/17/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809509151
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34,865.00 05/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806255797
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,800.00 05/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806255799
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 05/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806255803
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 05/17/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806255877
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 05/04/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255617
Principal investigator 1 GlaxoSmithKline, LLC. $2,386.80 04/29/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809520487
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,575.94 04/27/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255629
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,478.97 04/27/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255639
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $293.34 04/27/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256015
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $293.34 04/22/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256011
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $750.00 04/20/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255633
Principal investigator 1 GlaxoSmithKline, LLC. $2,386.80 04/19/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809520481
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $293.34 04/16/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $586.68 04/09/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256005
Principal investigator 1 GlaxoSmithKline, LLC. $2,386.80 04/08/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809547715
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,776.00 03/30/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256077
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,778.00 03/30/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256097
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,693.44 03/30/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256113
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,347.00 03/25/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256065
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,600.00 03/24/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 806255791
Principal investigator 1 GlaxoSmithKline, LLC. $2,386.80 03/23/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY & ASTHMA
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 809546339
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 03/23/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255573
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,000.00 03/23/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255583
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,242.62 03/16/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255561
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,511.15 03/09/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255577
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 03/09/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255581
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,796.00 03/04/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256041
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $798.00 03/04/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256085
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $586.68 03/04/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256213
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,245.00 03/01/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256039
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,596.00 03/01/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256081
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.02 03/01/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256101
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $898.00 02/15/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256047
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $798.00 02/15/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256087
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $293.34 02/15/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806256103
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21,200.40 02/09/2021 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Care
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806255587
Principal investigator 1 Eli Lilly and Company $59.40 01/26/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 819457749
Principal investigator 1 Novartis Pharmaceuticals Corporation $47,252.37 01/07/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. No dispute reported 06/30/2026 800629743
Principal investigator 1 Eli Lilly and Company $20,117.00 01/05/2021 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 819457253